TY - JOUR
T1 - Microbiota-Brain-Gut Axis and Neurodegenerative Diseases
AU - Quigley, Eamonn M.M.
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Purpose of Review: The purposes of this review were as follows: first, to provide an overview of the gut microbiota and its interactions with the gut and the central nervous system (the microbiota-gut-brain axis) in health, second, to review the relevance of this axis to the pathogenesis of neurodegenerative diseases, such as Parkinson’s disease, and, finally, to assess the potential for microbiota-targeted therapies. Recent Findings: Work on animal models has established the microbiota-gut-brain axis as a real phenomenon; to date, the evidence for its operation in man has been limited and has been confronted by considerable logistical challenges. Animal and translational models have incriminated a disturbed gut microbiota in a number of CNS disorders, including Parkinson’s disease; data from human studies is scanty. While a theoretical basis can be developed for the use of microbiota-directed therapies in neurodegenerative disorders, support is yet to come from high-quality clinical trials. Summary: In theory, a role for the microbiota-gut-brain axis is highly plausible; clinical confirmation is awaited.
AB - Purpose of Review: The purposes of this review were as follows: first, to provide an overview of the gut microbiota and its interactions with the gut and the central nervous system (the microbiota-gut-brain axis) in health, second, to review the relevance of this axis to the pathogenesis of neurodegenerative diseases, such as Parkinson’s disease, and, finally, to assess the potential for microbiota-targeted therapies. Recent Findings: Work on animal models has established the microbiota-gut-brain axis as a real phenomenon; to date, the evidence for its operation in man has been limited and has been confronted by considerable logistical challenges. Animal and translational models have incriminated a disturbed gut microbiota in a number of CNS disorders, including Parkinson’s disease; data from human studies is scanty. While a theoretical basis can be developed for the use of microbiota-directed therapies in neurodegenerative disorders, support is yet to come from high-quality clinical trials. Summary: In theory, a role for the microbiota-gut-brain axis is highly plausible; clinical confirmation is awaited.
KW - Alzheimer’s disease
KW - Antibiotics
KW - Fecal microbiota transplantation
KW - Gut-brain axis
KW - Microbiome
KW - Microbiota
KW - Neurodegenerative diseases
KW - Parkinson’s disease
KW - Probiotics
UR - http://www.scopus.com/inward/record.url?scp=85032031823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032031823&partnerID=8YFLogxK
U2 - 10.1007/s11910-017-0802-6
DO - 10.1007/s11910-017-0802-6
M3 - Review article
C2 - 29039142
AN - SCOPUS:85032031823
SN - 1528-4042
VL - 17
JO - Current Neurology and Neuroscience Reports
JF - Current Neurology and Neuroscience Reports
IS - 12
M1 - 94
ER -